BHCM
AVXL icon

Brevan Howard Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Brevan Howard Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-69,638
Closed -$214K – 2087
2026
Q1 		$214K Buy
69,638
+14,911
+27% +$64.6K ﹤0.01% 1858
2025
Q4 		$195K Buy
54,727
+37,503
+218% +$230K ﹤0.01% 1588
2025
Q3 		$153K Buy
+17,224
New +$175K ﹤0.01% 1810
2025
Q2 		– Sell
-10,932
Closed -$93.8K – 1838
2025
Q1 		$93.8K Buy
+10,932
New +$103K ﹤0.01% 1055
2024
Q3 		– Sell
-25,801
Closed -$109K – 1137
2024
Q2 		$109K Buy
+25,801
New +$104K ﹤0.01% 963

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brevan Howard Capital Management's AVXL Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 69,638 shares — an estimated $214K sold.

Brevan Howard Capital Management first reported a position in AVXL in Q2 2024 and held it in 5 quarters. The position peaked at $214K in Q1 2026. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 69,638 Anavex Life Sciences shares in Q2 2026, an estimated $214K.
  • Brevan Howard Capital Management first reported a position in Anavex Life Sciences in Q2 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's Anavex Life Sciences position peaked at $214K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.